(Date:11/22/2009)... 23, 2009 UT Southwestern Medical Center is among...es of Health to share $56 million over five years .... , The ICAC, which receives funding through th...us Diseases, investigates novel treatments and cau...uchalla, chief of allergy and immunology at UT Sou...
(Date:11/22/2009)...surface, bacteria are abundant, diverse and consta...the University of California, San Diego School of ... on the skin surface trigger a pathway that preven... germs are actually good for us," said Richard L. ...cs, chief of UCSD,s Division of Dermatology and th...
(Date:11/22/2009)... HealthSmart, an innovative healthcare be...as successfully completed a recapitalization with ... other lenders. Silver Point Capital, L.P. is a p...icut. This recapitalization allows the Company to...rategy. , , (PRWEB) Nove...
(Date:11/21/2009)...INGTON, Nov. 21 Tonight...ceed to Senator Reid,s version of the government t...nable items included in this bill; like the public...government funding for elective abortion, which is...ionally the bill provides subsidies for private pl...
(Date:11/21/2009)...HINGTON, Nov. 21 A regi... onchocerciasis (river blindness) in the Americas ...sease in recent years, as evidenced by a 31% decre...ug administration in six endemic countries. Resul...of the American Society of Tropical Medicine and H...
Breaking Medicine News(10 mins):Health News:UT Southwestern receives continued NIH funding for Inner City Asthma Consortium 2Health News:Surface bacteria maintain skin's healthy balance 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4(Date:11/20/2009)...PRNewswire/ -- Reportlinker.com announces that a n...logue. ,, Medical Adhesives and Sealants - A U...om/p0164242/Medical-Adhesives-and-Sealants---A-US-...edium=pr&utm_campaign=prnewswire ,, The u...eeminence in medical devices and equipments. Cutti...
(Date:11/20/2009)...v. 20 BD (Becton, Dickin...e completion of its acquisition of HandyLab, Inc.,...s and manufactures molecular diagnostic assays and...andyLab announced an exclusive agreement for BD to... HandyLab Jaguar(TM) platform, the first fully int...
(Date:11/19/2009)...RNewswire/ -- In response to an ever-increasing nu...edicines, Operation Pangea II, involving 24 countr...lth Organization,s International Medical Products ...t the dangers of buying medicines online. ,, Th... of arrests and the seizure of thousands of potent...
Breaking Medicine Technology:Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2First Potential Lupus Specific Treatment in Sight 4744 1First Potential Lupus Specific Treatment in Sight 4744 2First Potential Lupus Specific Treatment in Sight 4744 3Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 1Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 2Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 3Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 4Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 5Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 6Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 7Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 8Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 9Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA 28TM 29 in Systemic Lupus Erythematosus 4741 10Waging War on Wrinkles 3A Infini Cosmetic Associates Now Offers Recent FDA Approved Dysport The Botox Alternative 52054 1Waging War on Wrinkles 3A Infini Cosmetic Associates Now Offers Recent FDA Approved Dysport The Botox Alternative 52054 2...NCETON, N.J., Dec. 11 Pharmasset, Inc.,(Nasdaq: ...ommitted to,discovering, developing and commercial...ted financial results for the fiscal year ended Se... held $63.6 million in cash and cash,equivalents a... and 2008 Highlights , Clevudine , Dur...
... VEGAS, Dec. 11 CardioVascular BioTherapeutics, I...t two additional hospitals in the United States op... clinical trial for the treatment of severe corona...Institute Foundation in Minneapolis MN, and Prince... , Mercy Hospital Fairfield (Ohio) and The Chri...
Other Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial 2...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: